Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Zai Lab Limited Unsponsored ADR ZLAB

Healthcare  —  Biotechnology
24.98 (0.30) (1.19%) as of 25 Sep
Market cap
$2.9B
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Zai Lab Limited Unsponsored ADR (ZLAB) Business Profile

Updated before January 2025

Company Overview

Zai Lab Limited Unsponsored ADR (ZLAB) is a leading biopharmaceutical company headquartered in Shanghai, China. Founded in 2014 by Dr. Samantha Du, Zai Lab has rapidly emerged as a key player in the global healthcare industry. The company focuses on developing and commercializing innovative therapies to address unmet medical needs, particularly in oncology, autoimmune disorders, and infectious diseases. Dr. Samantha Du, the founder and CEO, brings extensive experience in the pharmaceutical industry, having held leadership roles at multinational companies and venture capital firms. Under her guidance, Zai Lab has expanded its operations globally, with offices in China, the United States, and other regions.

Core Business Segments

Oncology

Zai Lab’s oncology portfolio is its flagship segment, featuring a range of innovative therapies targeting various types of cancer. Key products include:

  • ZEJULA (niraparib): A PARP inhibitor used for the treatment of ovarian cancer.
  • Optune: A device for treating glioblastoma, a type of brain cancer.
  • Odronextamab: A bispecific antibody targeting B-cell malignancies.

Autoimmune Disorders

In the autoimmune segment, Zai Lab focuses on therapies for chronic and debilitating conditions. Notable products include:

  • VYVGART (efgartigimod): A treatment for generalized myasthenia gravis.
  • ZL-1102: A topical IL-17A inhibitor for autoimmune skin diseases.

Infectious Diseases

Zai Lab is also active in combating infectious diseases, with a focus on innovative antibiotics and antiviral therapies. Key products include:

  • NUZYRA (omadacycline): A broad-spectrum antibiotic for community-acquired bacterial infections.
  • Sulbactam-durlobactam (SUL-DUR): A novel therapy for multidrug-resistant infections.

Business Model

Zai Lab operates on a hybrid business model that combines in-house research and development (R&D) with strategic partnerships and licensing agreements. The company collaborates with global pharmaceutical leaders to bring cutting-edge therapies to the Chinese market while also developing its own pipeline of innovative drugs. Revenue is generated through product sales, licensing fees, and milestone payments from partners. Zai Lab’s integrated approach allows it to accelerate the development and commercialization of therapies, ensuring a steady revenue stream and a robust product pipeline.

Strategic Direction

Zai Lab is committed to expanding its global footprint and enhancing its R&D capabilities. Key strategic initiatives include:

  • Pipeline Expansion: The company aims to broaden its portfolio by investing in next-generation therapies, including cell and gene therapies.
  • Geographic Growth: Zai Lab plans to strengthen its presence in the U.S. and European markets while continuing to dominate the Chinese market.
  • Sustainability Goals: The company is focused on reducing its environmental impact by adopting sustainable practices in manufacturing and operations.
  • Digital Transformation: Leveraging artificial intelligence and big data to optimize drug discovery and development processes.

Competitive Landscape

Zai Lab operates in a highly competitive environment, facing competition from both multinational pharmaceutical giants and local Chinese companies. Key competitors include:

  • Roche: A global leader in oncology and autoimmune therapies.
  • AstraZeneca: Known for its strong presence in oncology and respiratory diseases.
  • BeiGene: A Chinese biopharmaceutical company with a focus on oncology.
  • Innovent Biologics: Another Chinese competitor specializing in biologics for cancer and autoimmune diseases.

Risk Factors

Zai Lab faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: Stringent regulatory requirements in different markets can delay product approvals.
  • Market Dependence: Heavy reliance on a few key products for revenue generation.
  • Supply Chain Disruptions: Dependence on global supply chains for raw materials and manufacturing.
  • Competition: Intense competition from established players and new entrants.
  • R&D Risks: High costs and uncertainties associated with drug development.

Recent Developments

Zai Lab has made significant strides in recent years, including:

  • New Product Launches: The company recently launched VYVGART in China, marking a milestone in its autoimmune portfolio.
  • Partnerships: Zai Lab entered into a strategic collaboration with a leading biotech firm to co-develop a novel oncology therapy.
  • Regulatory Approvals: ZEJULA received approval for expanded indications in China, boosting its market potential.
  • Global Expansion: The company opened a new R&D center in the United States to accelerate innovation.

Investment Considerations

Strengths

  • Strong Pipeline: A diverse portfolio of innovative therapies across multiple therapeutic areas.
  • Global Partnerships: Collaborations with leading pharmaceutical companies enhance its competitive edge.
  • Market Leadership: Dominant position in the Chinese biopharmaceutical market.

Risks

  • High R&D Costs: Significant investment in research and development could impact profitability.
  • Regulatory Risks: Delays in product approvals could affect revenue growth.
  • Market Competition: Intense competition from global and local players.

Conclusion

Zai Lab Limited Unsponsored ADR (ZLAB) is a dynamic and innovative biopharmaceutical company with a strong focus on addressing unmet medical needs. With a robust product pipeline, strategic partnerships, and a commitment to sustainability, Zai Lab is well-positioned for future growth. However, investors should carefully consider the risks associated with regulatory challenges, market competition, and high R&D costs. Overall, Zai Lab represents a compelling investment opportunity in the rapidly evolving healthcare sector.